Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Addex Therapeutics (ADXN) Net Cash Flow: 2022-2024

Historic Net Cash Flow for Addex Therapeutics (ADXN) over the last 3 years, with Dec 2024 value amounting to $664.6 billion.

  • Addex Therapeutics' Net Cash Flow fell 71.27% to $664.6 billion in Q4 2024 from the same period last year, while for Dec 2024 it was -$7.4 billion, marking a year-over-year increase of 58.08%. This contributed to the annual value of -$708,648 for FY2024, which is 76.73% up from last year.
  • According to the latest figures from Q4 2024, Addex Therapeutics' Net Cash Flow is $664.6 billion, which was up 198.90% from -$672.0 billion recorded in Q3 2024.
  • Addex Therapeutics' 5-year Net Cash Flow high stood at $2,313.4 billion for Q4 2023, and its period low was -$2,764.5 billion during Q3 2023.
  • Its 3-year average for Net Cash Flow is -$2.1 billion, with a median of -$2.8 million in 2022.
  • Examining YoY changes over the last 5 years, Addex Therapeutics' Net Cash Flow showed a top increase of 68,771,174.44% in 2023 and a maximum decrease of 178,495,163.18% in 2023.
  • Addex Therapeutics' Net Cash Flow (Quarterly) stood at -$3.4 million in 2022, then skyrocketed by 68,771,174.44% to $2,313.4 billion in 2023, then tumbled by 71.27% to $664.6 billion in 2024.
  • Its Net Cash Flow stands at $664.6 billion for Q4 2024, versus -$672.0 billion for Q3 2024 and -$3.4 million for Q2 2024.